Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyDiseaseAmpullary CancerSmall Bowel CarcinomaSubgroupICD10C17.-C24.1MeSHCommon Bile Duct NeoplasmsDuodenal NeoplasmsIleal NeoplasmsJejunal NeoplasmsSequenceChemotherapyChemo-substanceBevacizumabCapecitabineOxaliplatinPembrolizumabChemo-substanceBevacizumabCapecitabineOxaliplatinPembrolizumabChemo-substanceBevacizumabCapecitabineOxaliplatinPembrolizumabChemo-substanceBevacizumabCapecitabineOxaliplatinPembrolizumabNo. Substances13 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronNo. Substances13Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksAbdominal PainAnemia Hb below 10g/dlDiarrheaEmetogenicity (MASCC/ESMO)FatigueHypertensionHyperthyroidismHypothyroidismIncrease AminotransferasesNeutropeniaPruritusRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorGulhati PPedersen KSDiseaseAdenokarzinom des Dünndarms oder der Papilla Vateri, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes Dünndarm-Ca, mindestens 1 Vortherapie, ECOG 0-1OriginHematology/Oncology Fellowship Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TexasWashington University, St. Louis, Missouri, ZEBRA trialProtocols in Revision 2 protocols foundProtocols under revision.CAPOX (Capecitabine 750 / Oxaliplatin130) / Bevacizumab 7.5, Small bowel Cancer or Ampullary Cancer (PID490 V1.1)Pembrolizumab 200, Cancer of the Small Intestine (PID2356 V1.0)
